CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments (2015 - 2026)

CytomX Therapeutics' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $50.0 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 0.99% year-over-year to $50.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.5 million (down 49.23% YoY) and the FY2025 annual result came in at $133.0 million, down 47.95% from the prior year.
• Change in Acquisitions & Divestments was $50.0 million for Q1 2026 at CytomX Therapeutics, up from $30.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $125.0 million in Q4 2023 and bottomed at $20.0 million in Q3 2025.
• A 5-year average of $62.6 million and a median of $50.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments climbed 25.0% — and 2025, when it sank 71.74%.
• CytomX Therapeutics' Change in Acquisitions & Divestments stood at $100.0 million in 2022, then increased by 25.0% to $125.0 million in 2023, then slumped by 48.0% to $65.0 million in 2024, then tumbled by 53.85% to $30.0 million in 2025, then surged by 66.67% to $50.0 million in 2026.
• Business Quant data shows CTMX's Change in Acquisitions & Divestments at $50.0 million in Q1 2026, $30.0 million in Q4 2025, and $20.0 million in Q3 2025.